Theta Pharmaceuticals Ltd (SYNCOM) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 533157 | NSE: SYNCOM | Pharmaceuticals & Drugs | Small Cap

Theta Pharmaceutical Share Price

4.12 0.00 0.00%
as on 28-Jun'21 18:01

Theta Pharmaceuticals Ltd (SYNCOM) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 533157 | NSE: SYNCOM | Pharmaceuticals & Drugs | Small Cap

DeciZen - make an informed investing decision on Theta Pharmaceutical

Based on:

M-Cap below 100cr DeciZen not available

Theta Pharmaceuticals stock performance -

Key Ratios
mw4me loader
P/E Ratio (SA):
0.00
Market Cap:
16.5 Cr.
52-wk low:
4
52-wk high:
4.3

Is an attractive stock to invest in?


Login to view analysis.

10 Year X-Ray of Theta Pharmaceutical:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.

Value Creation

Value Creation Index Colour Code Guide

Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24TTM
ROCE % -0.4%-0.5%-45.7%-94.8%-37.7%-66.7%-54.3%-24.1%-29.5%-29.6%-
Value Creation
Index
-1.0-1.0-4.3-7.8NANANANANANA-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 61.962.952.841.564.1201.81.134.92
Sales YoY Gr.-1.7%-16%-21.4%54.4%-68.9%-90.8%-39.3%172.1%61.3%-
Adj EPS -1-0.9-9.3-7.5-2.9-2.9-1.2-7.6-15.2-17.1-1.1
YoY Gr.-NANANANANANANANANA-
BVPS (₹) 40.639.8192.6-0.2-3.1-4.36.1-9.1-26.2-4.3
Adj Net
Profit
-3.9-3.6-37-30.1-11.4-11.7-4.9-2.7-5.4-6.1-5
Cash Flow from Ops. 11.40.23.95.71.3-0.12.3-5.3-2.1-1.1-
Debt/CF from Ops. 2.5152.36.74.418.1-271.310.4-2.5-9.2-20.6-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales -24.6%-40.3%38.6%61.3%
Adj EPS NANANANA
BVPS-195.3%NANANA
Share Price -8.1% 14.7% - -

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24TTM
Return on
Equity %
-2.4-2.2-31.3-69.5-239.2176.13335.41016.8977.4
Op. Profit
Mgn %
2.51-4.3-12.4-2.9-9.2-179.1-126.1-67.1-65.2-164.9
Net Profit
Mgn %
-6.3-5.8-70.1-72.4-17.8-58.7-268-241.4-178.7-124.8-243
Debt to
Equity
0.20.20.32.4-26.5-1.9-1.46.2-6-2.4-
Working Cap
Days
5434594804552233639131,365731559531
Cash Conv.
Cycle
2102031881066-63-30-209123122-1,340

Recent Performance Summary

Login to view analysis.
Login to view analysis.

Latest Financials - Theta Pharmaceuticals Ltd.

Standalone Consolidated
TTM EPS (₹) -1.1 -19.6
TTM Sales (₹ Cr.) 1.9 41.5
BVPS (₹.) -4.3 2.6
Reserves (₹ Cr.) -57 -30
P/BV -0.95 1.57
PE 0.00 0.00
From the Market
52 Week Low / High (₹) 3.95 / 4.33
All Time Low / High (₹) 0.65 / 162.40
Market Cap (₹ Cr.) 16.5
Equity (₹ Cr.) 40
Face Value (₹) 10
Industry PE 40.6

Management X-Ray of Theta Pharmaceutical:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Theta Pharmaceutical - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios of Theta Pharmaceutical

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Sales61.8662.9252.8441.5364.1219.971.831.113.024.87
Operating Expenses 60.2962.2955.1346.7465.9921.795.112.515.048.05
Manufacturing Costs10.0915.713.944.695.301.620.240.060.610.88
Material Costs34.2531.1135.7324.2040.3712.782.571.112.173.33
Employee Cost 8.178.978.8310.3011.2951.680.441.862.89
Other Costs 7.796.506.627.559.032.390.620.910.400.94
Operating Profit 1.570.63-2.29-5.21-1.86-1.83-3.28-1.40-2.02-3.18
Operating Profit Margin (%) 2.5%1.0%-4.3%-12.6%-2.9%-9.2%-179.0%-126.0%-67.1%-65.2%
Other Income 2.982.982.280.440.310.260.390.120.060.76
Interest 4.573.313.100.280.410.290.0201.381.73
Depreciation 5.344.634.613.742.932.291.991.402.051.93
Exceptional Items 00-62.19-56.73-6.51-7.570000
Profit Before Tax -5.35-4.33-69.90-65.52-11.42-11.72-4.91-2.68-5.39-6.07
Tax -1.53-0.807.910000000
Profit After Tax -3.82-3.53-77.81-65.52-11.42-11.72-4.91-2.68-5.39-6.07
PAT Margin (%) -6.2%-5.6%-147.0%-157.0%-17.8%-58.7%-268.0%-241.0%-178.0%-124.0%
Adjusted EPS (₹)-1.0-0.9-19.5-16.4-2.9-2.9-1.2-7.6-15.2-17.1
Dividend Payout Ratio (%)0%0%0%0%0%0%0%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24

Equity and Liabilities

Shareholders Fund 163.67160.1676.0710.47-0.90-12.42-17.322.16-3.22-9.30
Share Capital 404040404040403.553.553.55
Reserves 123.67120.1636.07-29.53-40.90-52.42-57.32-1.39-6.77-12.85
Minority Interest0000000000
Debt27.5829.9622.831823.9223.6524.0713.3919.2022.60
Long Term Debt12.8610.708.344.7611.6911.7011.608.106.904.82
Short Term Debt14.7219.2614.4913.2412.2311.9512.475.2912.3017.79
Trade Payables6.227.6113.0721.3423.065.455.210.642.852.01
Others Liabilities -2.42-4.055.3911.053.391.135.351.392.244.12
Total Liabilities 195.06193.68117.3660.8749.4617.8317.3117.5921.0719.44

Fixed Assets

Gross Block45.6546.8423.9724.1024.2124.1924.1924.9230.4031.28
Accumulated Depreciation22.2026.153.897.6210.5612.8114.8115.9517.8919.71
Net Fixed Assets 23.4620.6920.0816.4813.6611.379.388.9612.5111.57
CWIP 00000003.7300
Investments 90.8190.8136.320000000
Inventories13.3113.3510.809.537.092.010.450.241.500.78
Trade Receivables26.5830.5619.8716.8317.840.250.160.091.691.99
Cash Equivalents 0.801.370.450.561.401.134.080.440.950.56
Others Assets 40.1036.9029.8317.479.473.063.244.144.424.55
Total Assets 195.06193.68117.3660.8749.4617.8317.3117.5921.0719.44

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Cash Flow From Operating Activity 11.380.203.935.691.32-0.092.32-5.32-2.08-1.10
PBT -5.35-4.33-69.90-65.52-11.37-11.51-4.91-2.68-5.39-6.07
Adjustment 8.766.8868.0260.319.452.201.881.333.393.63
Changes in Working Capital 8.23-2.156.7110.93.259.225.35-3.97-0.091.34
Tax Paid -0.27-0.20-0.900000000
Cash Flow From Investing Activity 1.691.225.10-0.97-0.250.56-2.94-0.21-1.85-0.96
Capex 0.250.07-2.44-0.13-0.11000-5.59-0.98
Net Investments -1.01-1.4100-0.760.450000
Others 2.452.557.54-0.830.620.10-2.94-0.213.740.03
Cash Flow From Financing Activity -12.88-0.93-9.62-4.85-0.99-0.290.485.354.431.67
Net Proceeds from Shares 00000003.5500
Net Proceeds from Borrowing 0000000000
Interest Paid -4.57-3.31-2.87-0.020-0.02-0.020.01-1.37-1.73
Dividend Paid 0000000000
Others -8.312.38-6.75-4.83-0.99-0.260.511.785.813.40
Net Cash Flow 0.190.49-0.60-0.120.080.18-0.14-0.180.49-0.39

Finance Ratio

PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Ratios
ROE (%)-2.33-2.2-66.16-151.43N/AN/AN/A0N/AN/A
ROCE (%)-0.4-0.54-45.67-94.84N/AN/AN/A-24.05N/AN/A
Asset Turnover Ratio0.290.320.340.471.160.590.10.060.160.24
PAT to CFO Conversion(x)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Working Capital Days
Receivable Days208166173160991654140118138
Inventory Days75778389478324511321285
Payable Days13481106260201407756966698267

Theta Pharmaceuticals Ltd Stock News

Theta Pharmaceuticals Ltd FAQs

The current trading price of Theta Pharmaceutical on 28-Jun-2021 18:01 is ₹4.12.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 27-Jun-2021 the market cap of Theta Pharmaceutical stood at ₹16.48.
The latest P/E ratio of Theta Pharmaceutical as of 27-Jun-2021 is 0.00.
The latest P/B ratio of Theta Pharmaceutical as of 27-Jun-2021 is -0.95.
The 52-week high of Theta Pharmaceutical is ₹4.33 and the 52-week low is ₹3.95.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Theta Pharmaceutical is ₹1.86 ( Cr.) .

About Theta Pharmaceuticals Ltd

The Company was originally incorporated as Syncom Healthcare Limited on July 29, 2002 by Registrar of Companies, Maharashtra, Mumbai. The Certificate for Commencement of business was granted on August 2, 2002. The company has been promoted by Ajay Bankda & Jyoti Bankda. The company was formed for manufacturing, marketing & trading of pharmaceuticals formulations under its own brands in Ethical, OTC, Generic and Herbal market segment.

Initially it started its journey with the marketing of the pharmaceuticals products manufactured by others under its own brand and in year 2006, the company set up a State of Art manufacturing unit at Dehradun in Uttarakhand. The unit was commissioned in November, 2006. During the year ended March 31, 2007, the net profit before tax & extra-ordinary items, of the Company increased to Rs.331.38 lakh from Rs.32.20 lakh during the year ended March 31, 2006 due to commencement of manufacturing of the various products in its own manufacturing unit and marketing through a strong distribution network.

SHL started as a marketing Company, which was outsourcing its requirement of finished products (Under Its Own Brand And Drug License) from other formulation manufacturing units based in and around Indore. Presently also SHL is outsourcing some of its requirement of finished products. With these companies, Syncom has a purchase and sale arrangement where the supplier unit is manufacturing SHL’s products on SHL’s specification and under SHL’s quality control under which SHL controls the quality of raw material, their sourcing by the supplier as well as production in the units of these suppliers. The manufactured goods, manufactured for SHL are sold to SHL on pre-decided order prices for each formulation product so manufactured.

To cater the diversified and increased demand the Company planned to set up its own pharmaceutical manufacturing facilities. Accordingly, the company set up a manufacturing facility at Dehradun in the state of Uttrakhand, which is a Tax free & duty free Zone. The Company set up its Plant at Dehradun and it started the commercial production in November, 2006. Presently Company is Manufacturing, Marketing and Distributing its Pharmaceutical Formulations under own Brands of Ethical, OTC, Generic and Herbal market segment.

Product range of the company:

Syncom has presence in Pharmaceuticals Formulations which can be categorized in 4 broad categories i.e. Generic, OTC, Ethical and Herbal. The company manufactures a range of products such as Ethical drugs, Generic drugs, over the counter drugs (OTC) and Herbal formulations in various dosage forms and markets them under the trade mark ‘Syncom’ which is a registered trademark in the name of Syncom Healthcare Limited. The company also undertakes contract manufacturing for large variety of pharmaceutical formulations for a number of other pharmaceutical companies of national and international repute such as Lupin Limited, Nicholas Piramal India Ltd, Galpha Laboratories Limited, Percos India Pvt. Ltd etc. (under their own brands) located in India.

The company manufactures various dosage forms, which include tablets, capsules, eye/ear drops, ointment and creams and dry syrups. The company has an established product-marketing network covering both metro and minimetro cities, which enable it to reach the existing and potential customers through the network of distributors and dealers spread across the country. For the purpose of marketing the various products, the Company’s business has been categorized as Branded Generic Division, Over the Counter (OTC), Ethical division and Contract Manufacturing Division.

The Company is producing more than 130 products in Generic segment which includes CTZ, Profeed, Nimjet, Divoron, Gentijet, Ciprojet, etc.

Apart form Generic, the Company has developed presence in OTC Segment. The Company is producing more than 40 products in this segment which include Fastac, Q-coril, Triple action, Pandrop, Syncom Gripe Water, etc. Having built-up a presence in Generic & OTC segment and as a measure to expand and grow, the Company has also entered into Ethical segment. Syncom has developed more than 20 products in this segment which includes Fresca, Flusa, Nutone, Busera, etc.

Syncom is also having presence in Herbal segment with around 25 products which includes Patton, Attom, Narisudha, Salony Cream, etc.

Milestones:

  • 2002 - Incorporation of Syncom Healthcare Limited
  • 2002 - Syncom Healthcare Limited started marketing operations
  • 2005 - Commenced setting up of manufacturing facility at Selaqui, Dehradun
  • 2006 - Start of commercial production at Dehradun Industrial Unit for its own marketing
  • 2007 - Entered into agreement for Contract manufacturing with Lupin Limited, Galpha Laboratories, Nicholas Piramal, etc. Pharmaceutical Companies for manufacturing its various range of products.
To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×